We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 142,735 | 07:46:26 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
From Apr 2021 to Apr 2024
By Adam Clark
Evgen Pharma PLC shares surged on Thursday after it said that its SFX-01 product to treat malignant glioma has been granted an orphan drug designation by the U.S. Food and Drug Administration.
The designation confers intellectual property cover to an investigational drug in the form of data protection at the time of approval of a new drug application. Tax credits are also possible on eventual U.S. sales of an approved orphan drug.
"This is part of a wider strategy to access the U.S. market and positions us well for further investigations of our lead asset in this devastating brain cancer as we continue to optimize SFX-01 for clinical trials and eventually partnering," Evgen Chief Executive Huw Jones said.
Shares at 1007 GMT were up 2.50 pence, or 39%, at 8.90 pence.
Write to Adam Clark at adam.clark@dowjones.com
(END) Dow Jones Newswires
September 02, 2021 06:31 ET (10:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Evgen Pharma Chart |
1 Month Evgen Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
